Skip to content

Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

A Prospective, Single-arm, Multinational, Multi-center, Clinical Study to Evaluate the Performance and Safety of Musculoskeletal Embolization Using NBGM200 in Patients With Knee Degenerative Osteoarthritis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06930677
Enrollment
72
Registered
2025-04-16
Start date
2025-04-17
Completion date
2027-02-28
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis (Knee OA)

Brief summary

Study in patients with knee osteoarthritis treated by embolization using NBGM200

Interventions

MSK embolization

Sponsors

Next Biomedical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Osteoarthritis proven by MR-imaging

Exclusion criteria

* Current local infection * Life expectancy less than 6 months

Design outcomes

Primary

MeasureTime frameDescription
Knee Injury and Osteoarthritis Outcome score (KOOS-12)6 months post treatmentKnee Injury and Osteoarthritis Outcome score (KOOS-12) is to evaluate the pain, function and quality of life. The total score ranges from 0 to 100, where higher scores indicate better outcomes.

Secondary

MeasureTime frameDescription
Visual Analog Scale(VAS)6 months post treatmentVisual Analog Scale(VAS) is to evaluate the pain from 0 to 10. Higher scores indicate worse outcomes, representing more severe pain
Whole Organ Magnetic Resonance Imaging Score (WORMS)6 months post treatmentWhole Organ Magnetic Resonance Imaging Score (WORMS) is a semi-quantitative scoring method for multi-feature, whole-organ evaluation of knee OA based on MRI. The total score ranges from 0 to 332, with higher scores indicating worse outcomes.

Countries

Belgium, Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026